NuVasive - NUVA Stock Forecast, Price & News

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NUVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NUVA, but not buy additional shares or sell existing shares.
View NUVA analyst ratings or view top-rated stocks.

11 equities research analysts have issued 1 year price objectives for NuVasive's stock. Their NUVA share price forecasts range from $44.50 to $58.00. On average, they expect the company's share price to reach $50.77 in the next twelve months. This suggests a possible upside of 36.9% from the stock's current price.
View analysts price targets for NUVA or view top-rated stocks among Wall Street analysts.

NuVasive's stock was trading at $41.24 on January 1st, 2023. Since then, NUVA stock has decreased by 10.1% and is now trading at $37.08.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our NUVA earnings forecast.

NuVasive, Inc. (NASDAQ:NUVA) released its quarterly earnings results on Wednesday, February, 22nd. The medical device company reported $0.43 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by $0.08. The medical device company earned $305.45 million during the quarter, compared to analyst estimates of $311.01 million. NuVasive had a net margin of 3.36% and a trailing twelve-month return on equity of 12.45%. The company's revenue for the quarter was up 1.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.40 earnings per share.

ETFs with the largest weight of NuVasive (NASDAQ:NUVA) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), ProShares Merger ETF (MRGR), Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Equipment ETF (XHE), Principal Healthcare Innovators ETF (BTEC), Invesco Nasdaq Future Gen 200 ETF (QQQS), iShares S&P Small-Cap 600 Value ETF (IJS) and Vanguard S&P Small-Cap 600 Value ETF (VIOV).

NuVasive declared that its Board of Directors has approved a stock repurchase plan on Tuesday, November 9th 2021, which allows the company to buyback $100,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 3.5% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's leadership believes its shares are undervalued.

NuVasive issued an update on its FY 2023 earnings guidance on Wednesday, February, 22nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.27 billion-$1.30 billion, compared to the consensus revenue estimate of $1.28 billion.

59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

NuVasive's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Thrivent Financial for Lutherans (6.18%), Dimensional Fund Advisors LP (2.78%), Paradice Investment Management LLC (2.67%), Geode Capital Management LLC (1.85%), Arrowstreet Capital Limited Partnership (1.58%) and Point72 Asset Management L.P. (1.57%). Insiders that own company stock include James Christopher Barry, Lucas Vitale, Massimo Calafiore and Matthew Link.
View institutional ownership trends.

Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NUVA stock can currently be purchased for approximately $37.08.

NuVasive (NASDAQ:NUVA) has a market capitalization of $1.94 billion and generates $1.20 billion in revenue each year. The medical device company earns $40.41 million in net income (profit) each year or $0.71 on an earnings per share basis.

The company employs 3,000 workers across the globe.

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134.